3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
6
Sunitinib
5
Bevacizumab
4
Sorafenib
3
Radiotherapy
3
Radiosurgery
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Interleukin-2
3
Cyclophosphamide
3
Axitinib
3
tivozanib
2
fludarabine phosphate
2
durvalumab
2
avelumab
2
atezolizumab
2
Peripheral Blood Stem Cell Transplantation
2
Optical Imaging
2
Nephrectomy
2
Gene Expression Profiling
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
tremelimumab
1
temsirolimus
1
siltuximab
1
sargramostim
1
pazopanib
1
pamiparib
1
milademetan
1
lenvatinib
1
fludarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Carcinoma, Renal Cell
×
bexmarilimab
×
Clear all
NCT05104905
2022-05-11
RENACOL
Faron Pharmaceuticals Ltd
Phase 1/2
Withdrawn